Literature DB >> 6352079

Hemodynamic patterns of response during long-term captopril therapy for severe chronic heart failure.

M Packer, N Medina, M Yushak, J Meller.   

Abstract

To determine the relationship between the early and late hemodynamic effects of captopril in patients with severe heart failure, we performed serial right heart catheterizations in 51 such patients who were treated with the drug for 2 to 8 weeks. Four hemodynamic patterns of response were observed. Nine patients had minimal responses initially (type I); six failed to improve during long-term treatment, but three showed delayed hemodynamic benefits. Twenty-eight patients had initial beneficial drug effects that were sustained after 48 hr and after 2 to 8 weeks (type II). In seven patients, first doses of captopril produced marked beneficial responses, but these became rapidly attenuated after 48 hr; nevertheless, continued therapy for 2 to 8 weeks was accompanied by spontaneous restoration of the hemodynamic effects of first doses of the drug, i.e., triphasic response (type III). In the remaining seven patients, attenuation of initial response was not reversed by prolonged captopril therapy; hemodynamic variables after 2 to 8 weeks had returned to their pretreatment values, i.e., drug tolerance (type IV). Plasma renin activity was lower in patients with minimal responses (0.6 +/- 0.2 ng/ml/hr) and was higher in patients with triphasic responses (9.4 +/- 2.5 ng/ml/hr) than in patients with types II and IV response patterns (4.4 +/- 0.7 and 2.8 +/- 0.5 ng/ml/hr, respectively; both p less than .05). Although first-dose effects of captopril are frequently sustained, the occurrence of delayed, attenuated, and triphasic responses indicates that a complex and variable relationship may exist between the early and late hemodynamic effects of vasodilator drugs in patients with severe heart failure.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6352079     DOI: 10.1161/01.cir.68.4.803

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  22 in total

Review 1.  Tissue and plasma angiotensin converting enzyme and the response to ACE inhibitor drugs.

Authors:  R J MacFadyen; K R Lees; J L Reid
Journal:  Br J Clin Pharmacol       Date:  1991-01       Impact factor: 4.335

Review 2.  Cardiac effects of angiotensin converting enzyme inhibitors.

Authors:  N Sharpe
Journal:  Cardiovasc Drugs Ther       Date:  1990-02       Impact factor: 3.727

Review 3.  Inhibitors of the renin-angiotensin system in established cardiac failure.

Authors:  K Chatterjee
Journal:  Heart       Date:  1996-11       Impact factor: 5.994

4.  Usefulness of plasma renin activity in predicting haemodynamic and clinical responses and survival during long term converting enzyme inhibition in severe chronic heart failure. Experience in 100 consecutive patients.

Authors:  M Packer; N Medina; M Yushak; W H Lee
Journal:  Br Heart J       Date:  1985-09

5.  Mortality in heart failure: clinical variables of prognostic value.

Authors:  J G Cleland; H J Dargie; I Ford
Journal:  Br Heart J       Date:  1987-12

Review 6.  New mechanisms for positive inotropic agents: focus on the discovery and development of imazodan.

Authors:  R E Weishaar; D Kobylarz-Singer; B A Klinkefus
Journal:  Cardiovasc Drugs Ther       Date:  1989-03       Impact factor: 3.727

Review 7.  WITHDRAWN: Diuretics for heart failure.

Authors:  Rajaa F Faris; Marcus Flather; Henry Purcell; Philip A Poole-Wilson; Andrew J S Coats
Journal:  Cochrane Database Syst Rev       Date:  2016-04-04

8.  Effects of captopril and a combination of hydralazine and isosorbide dinitrate on myocardial sympathetic tone in patients with severe congestive heart failure.

Authors:  P Daly; J L Rouleau; D Cousineau; J H Burgess; K Chatterjee
Journal:  Br Heart J       Date:  1986-08

Review 9.  The role of vasodilator therapy in the treatment of severe chronic heart failure.

Authors:  M Packer
Journal:  Drugs       Date:  1986       Impact factor: 9.546

Review 10.  Pharmacokinetic drug interactions with ACE inhibitors.

Authors:  H Shionoiri
Journal:  Clin Pharmacokinet       Date:  1993-07       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.